It seemed like only a matter of time before someone would close this valve. After months of off-label prescribing of Ozempic, propelled by celebrity hype of the diabetes drug which has gained ...

Off‐label drug use in children refers to the prescribing of medicines outside the terms of their licensed marketing authorisation, whether by age, dosage, indication or route. It arises from a chronic ...

The US Food and Drug Administration (FDA) held a 2-day public hearing this week to solicit input about the marketing and use of medications and medical devices for off-label use. It is fairly common ...

The US Food and Drug Administration (FDA) finalized guidance to industry on allowable communications to health care providers about off-label drug and device uses. The Q&A document, issued on 6 ...

A consensus statement providing novel guidance for use of GLP-1 and GLP-1/GIP receptor agonists (GLP-1s and GIP/GLP-1s) in management of type 1 diabetes (T1D) was published today in Diabetes ...

As common—and costly—as off-label prescribing is in oncology, it is poorly understood. It is, by nature, hard to study. Yet it is clear that the practice is changing. Skyrocketing drug costs, ...

An off-label prescription drug has been shown to help some non-verbal children with autism discover the ability to speak. The drug, leucovorin, is a prescription vitamin that functions similarly to ...

With a look at 160 common medications, about one out of every five are prescribed off-label, according to recent research. This means that the drugs were used in ways never approved by the FDA.

In March 2023, I started working at a large retail pharmacy as a technician. Bright-eyed and bushy-tailed, I donned my crisp, blue technician’s uniform complete with my slightly lopsided name tag on ...

A new sociomedical perspective shows how off-label use of GLP-1 drugs for slimness is redefining what counts as a healthy, responsible body, revealing hidden moral pressures and global inequalities ...

A former employee says pharmaceutical giant Novo Nordisk targeted him after he raised concerns the drug was being pushed for weight loss via incentives.